Development of a tuberculosis vaccine to boost BCG is a major international health priority. SRL172, an inactivated whole cell booster derived from a non-tuberculous mycobacterium, is the only new vaccine against tuberculosis to have demonstrated efficacy in a Phase 3 trial. In the present study we sought to determine if a three-dose series of DAR-901 manufactured from the SRL172 master cell bank by a new, scalable method was safe and immunogenic.
von Reyn, C. Fordham; Lahey, Timothy; Arbeit, Robert D.; Landry, Bernard; Kailani, Leway; Adams, Lisa; Haynes, Brenda; Mackenzie, Todd; Wieland-Alter, Wendy; Connor, Ruth; Tvaroha, Sue; Hokey, David; Ginsberg, Ann; and Waddell, Richard, "Safety and Immunogenicity of an Inactivated Whole Cell Tuberculosis Vaccine Booster in Adults Primed with BCG: A Randomized, Controlled Trial of DAR-901" (2017). Open Dartmouth: Faculty Open Access Articles. 1719.